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Abstract. This study aimed to identify the CD24 and CD44 
immunophenotypes within invasive ductal breast carcinoma 
(IDC) subgroups defined by immunohistochesmistry markers 
and to determine its influence on prognosis as well as its 
association with the expression of Ki-67, cytokeratins (CK5 
and CK18) and claudin-7. Immunohistochemical expression 
of CD44 and CD24 alone or in combination was investigated 
in 95 IDC cases arranged in a tissue microarray (TMA). The 
association with subgroups defined as luminal A and B; HER2 
rich and triple negative, or with the other markers and prog-
nosis was analyzed. CD44+/CD24- and CD44-/CD24+ were 
respectively present in 8.4% and 16.8% of the tumors, a lack 
of both proteins was detected in 6.3%, while CD44+/CD24+ 
was observed in 45.3% of the tumors. Although there was no 
significant correlation between subgroups and different pheno-
types, the CD44+/CD24- phenotype was more common in the 
basal subgroups but absent in HER2 tumors, whereas luminal 
tumors are enriched in CD44-/CD24+ and CD44+/CD24+ cells. 
The frequency of CD44+/CD24- or CD44-/CD24+ was not 
associated with clinical characteristics or biological markers. 
There was also no significant association of these phenotypes 
with the event free (DFS) and overall survival (OS). Single 
CD44+ was evident in 57.9% of the tumors and was marginally 
associated to grading and not to any other tumor character-
istics as well as OS and DFS. CD24+ was positive in 74.7% 
of the tumors, showing a significant association with estrogen 
receptor, progesterone receptor and Ki-67 and a marginal 
association with CK18 and claudin-7. Expression of claudin-7 
and Ki-67 did not associate with the cancer subgroups, while a 
positive association between CK18 and the luminal subgroups 
was found (P=0.03). CK5, CK18 and Ki-67 expression had no 
influence in OS or DFS. Single CD24+ (P=0.07) and claudin-7 
positivity (P=0.05) were associated with reduced time of 
recurrence, suggesting a contribution of these markers to 
aggressiveness of breast cancer. 
Introduction
Breast carcinoma is a disease which is known for its striking 
histopathological heterogeneity recognized for a long time and 
which is classified into several histological subtypes (1).
In recent years, molecular profiling technologies have 
provided further evidence that breast cancer is a heteroge-
neous disease at the molecular level. The major breast cancer 
biological subtypes have been defined by gene expression 
profiles (2) or histochemical biomarkers (3) and have led to 
a working model for breast cancer molecular taxonomy (4). 
According to this classification, breast cancers can be subdi-
vided into luminal tumors expressing estrogen receptor (ER) 
and the progesterone receptor (PR) (ER+/PR+) which may be 
further subclassified into luminal A and luminal B tumors. 
The latter subtype exhibits either HER2 positivity or high 
expression of the proliferation marker Ki-67 (5). There are 
two ER/PR negative subtypes: HER2 rich (ER-/PR-/HER2+), 
and triple negative (negative for the three markers). These 
subtypes of breast cancer show distinct behaviors related 
to prognosis, survival and response to specific therapies (1). 
Within the triple negative disease tumors two subtypes were 
identified: basal like and a new molecular subtype referred as 
claudinlow characterized by the low gene expression of claudins 
(claudin-4, claudin-7 and claudin-3) (6). It is possible that this 
heterogeneity is derived in part from the transformation of 
different subsets of stem/progenitor cells in each biological 
subtype as proposed by Dontu et al (7).
Cancer stem cells have been defined as a subset of tumor 
cells that display stem cell properties including self-renewal 
and differentiation, giving rise to several cell types in the 
tumor, contributing to its heterogeneity (8).
In breast cancer, a subpopulation of cells characterized by 
the surface markers CD44+/CD24low has been reported to be 
highly tumorigenic when injected into immunocompromised 
mice (9). Shipitsin et al (10) reported that gene expression 
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of CD44+ and CD24+ cells isolated from breast carcinomas 
exhibited distinct profiles and that the CD44+ profile showed 
genes consistent with a stem-cell like profile.
A correlation of the CD44+/CD24low phenotype with 
specific breast cancer subtypes has been previously reported. 
This tumor phenotype appears to be common in basal like 
tumors (11,12) and in triple negative tumors (13). It has been 
suggested that tumor cells with a CD44+CD24- subpopulation 
may have a worse clinical behavior (13,14). In contrast, other 
studies have not revealed a significant association of CD44+/
CD24- with a potential progress or recurrence (15,16). As 
tumorigenesis involves complex biological mechanisms, Park 
et al (12) recently highlighted the need for evaluation of CD44/
CD24 in combination with other markers.
Our aim in the present study was to investigate the expres-
sion of CD44 and CD24 alone or in combination with a series 
of invasive ductal breast carcinomas arranged in a tissue 
microarray (TMA). Results were related to tumor subtypes 
defined by the immunohistochemical markers: ER and PR, 
HER2 and to the expression of Ki-67, basal and luminal cyto-
keratins (CK5, CK6 and CK18) with special focus on the tight 
junction protein claudin-7. In addition, we investigated the 
clinicopathological and prognostic significance with respect 
to overall survival (OS) and disease-free survival (DFS) of the 
different combinations of CD44 and CD24 and of the analyzed 
biological markers.
Materials and methods
Subjects. The cohort was assembled from patients with 
primary ductal invasive breast carcinoma (IDC) diagnosed at 
the Instituto do Cancer Arnaldo Vieira de Carvalho between 
2001 and 2007 after approval by its Institutional Review 
Board. A total of 95 cases were retrieved from the medical 
files, and the following patient information was collected: age, 
histological classification, nuclear grade, tumor size, node 
status, tumor recurrences, regional and distant metastasis, 
treatment, disease-free survival (DFS), and overall survival 
(OS). Patients were enrolled according to the inclusion 
criteria consisting of suitable paraffin blocks for immunohis-
tochemistry, adequate clinicopathological data and sufficient 
follow-up. The Nottingham system was used for assessing 
tumor nuclear grading. In all IDC cases the treatment involved 
mastectomy, radiotherapy, chemotherapy and axillary lymph 
node dissection. Cases with a positive immunohistochemical 
ER analysis received hormone therapy. Median follow-up of 
the analyzed IDC cohort was 4.8 years. At the final follow-up 
(4.9 years), 66 (69.5%) IDC patients were alive and 27 (28.4%) 
died of the disease. Characteristics of this retrospective cohort 
are detailed in Table I.
TMA construction. For each case, all available hematoxylin 
and eosin (H&E)-stained sections were reviewed to confirm 
the diagnosis of IDC and to select a representative tumor area 
for TMA construction and immunostaining.
For TMA construction, H&E-stained slides from each 
paraffin-embedded tumor block were checked to select a 
morphologically representative tumor area, which was then 
selected to construct the TMA paraffin block. Two tissue cylin-
ders of each case with a diameter of 1 mm were punched from 
the marked tumor areas of each of the 95 donor paraffin blocks 
and distributed into 4 new recipient paraffin blocks using the 
Manual Tissue Arrayer I (Beecher Instruments, Silver Spring, 
MD, USA). Sections (3 µm) were cut from the TMA paraffin 
block using the paraffin tape-transfer system (Instrumedics, 
St. Louis, MO, USA). One section was stained with H&E to 
confirm the presence of the tumor by light microscopy, and 
standard slides were used for immunohistochemical analyses.
Immunohistochemistry. Monoclonal antibodies to CK5 (clone 
XM 26), CK6 (clone CHK6B), CK18 (clone DC10), PR (clone 
PgR636), Ki-67 (clone MIB1) and HER2 (polyclonal) were 
obtained from Dako (Dako, Denmark) and diluted 1:300, 
1:100, 1:800, 1:500, 1:400, 1:2000, respectively. Each slide 
was also stained with 1:50 anti-ER (Neomarkers, clone 6F-11), 
claudin-7 diluted 1:500 (clone AB5487; Abcam, Cambridge, 
MA), CD44 (clone DF1485), raised against all forms of CD44, 
diluted 1:100 (Novocastra Laboratories Ltd., Newcastle, 
UK) and CD24 (clone C-20), diluted 1:100 (Santa Cruz 
Biotechnology, Palo Alto, CA, USA).
Table I. Clinicopathological properties of the breast carci-
nomas evaluated.
Parameters Patients (%)
Age (years)
 Median (range) 58 (28-88)
Tumor size (cm)
 Median (range) 4.5 (0.4-12.0)
pTNM
 I 7 (7.4)
 II 41 (43.2)
 III 45 (47.4)
 IV 2 (2.1)
Nuclear grading
 I 2 (2.1)
 II 40 (42.1)
 III 52 (54.7)
 ND 1 (1.1)
Nodal status
 Positive 60 (63.2)
 Negative 33 (34.7)
 ND 2 (2.1)
Metastasis status
 M1 21 (22.1)
 M0 60 (63.2)
 ND 14 (14.7)
Condition
 Alive 66 (69.5)
 Deceased 27 (28.4)
 ND 2 (2.1)
ND, not known.
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After deparaffinazation and rehydration of tissue micro-
array sections from formalin-fixed paraffin embedded 
samples, antigen retrieval was performed in a pressure cooker. 
After primary antibody incubation and secondary biotinylated 
streptavidin-peroxidase amplification, antigen detection was 
carried out by a solution containing 3,3' diaminobenzidine 
(Sigma, USA) and 6% H2O2. Counterstaining was performed 
with Harris hematoxylin. Positive controls were included in 
each staining reaction and consisted of breast cancer known to 
express each of the antigens of interest.
An Allred score of ER and PR nuclear immunoreactivity 
≤2 was considered a negative result (17). For HER2 samples, 
lack of reactivity in <10% of the tumor cells was scored as 
0. Barely perceptible focal membrane staining was scored 
as 1. Weak to moderate staining observed in >10% of the 
tumor cells was defined as 2. Strong staining of the complete 
membrane in >10% of the tumor cells was scored as 3. Staining 
was considered positive only if samples scored 3+ according 
to the American Society of Clinical Oncology of American 
Pathologists recommendation. For basal cytokeratins (CK 5/6) 
and claudin-7, samples were considered positive if ≥10% of 
tumor cells were reactive.
Specimens that exhibited a positive staining in ≥20% of 
cells were considered as Ki-67 positive. Negative controls were 
performed by omission of the respective primary antibody. 
Normal breast tissue usually presents 2+ pattern of claudin-7 
expression and 1+ or 0 of CD24 and CD44. Therefore, 3+ 
usually represents overexpression.
CD44 and claudin-7 were considered positive when 
membranes were stained in a distinct and delicate pattern 
without reactive cytoplasm or nuclei. We used a HERcept test 
model for reporting results and the scoring was: 0, totally nega-
tive; 1+, 1-10% positive neoplastic cells; 2+, moderate staining 
in 10-30% of neoplastic cells; and 3+, >30% of strongly reactive 
neoplastic cells. CD24 was detected mainly in the cytoplasm 
and scoring was conducted as for CD44. Normal breast tissue 
usually presents a 2+ pattern of claudin-7 expression and 1+ 
or 0 for CD24 and CD44. Therefore, 3+ usually represents 
overexpression.
For the prognostic investigation and survival analysis, each 
individual immunophenotype pattern was evaluated for single 
CD44+ (CD44 positive cells), single CD24+ (CD24 positive 
cells) and four combinations, CD44+/CD24+, CD44-⁄CD24-, 
CD44+/CD24-, CD44-/CD24+.
Statistical methods. Correlation between antigen expression 
and other clinicopathological parameters was examined by the 
χ2 test. Survival probabilities were estimated by the univariate 
Kaplan-Meier method, survival curves were compared by the 
log-rank (Mantel-Haenszel method). SSPS version 10.0 for 
Windows was used. Statistical significance was set at p<0.05.
Results
A total of 95 patients with IDC were evaluated. The demo-
graphic and clinical data are summarized in Table I.
The frequency of the biological markers analyzed is 
shown in Table II. Nuclear immunoreactivity for ER and PR 
and Ki-67 was expressed in 47.4% and HER2 in 34.7% of the 
cases. Claudin-7 was detected in 38.9%, basal cytokeratin 5 in 
17.9% and CK18 in 61.1% of the cases. Tumors were mostly 
positive for either CD44 (57.9%) or CD24 (74.7%).
The pattern of CD44 expression was mainly membranous 
whereas CD24 was expressed predominantly in the cytoplasm. 
Claudin-7 was also expressed at the membrane and Ki-67 
immunostaining was exclusively nuclear. Positive cytokeratins 
5 and 18 were found in 17.9 and 61.1% of the cases, respec-
tively. CK6 was expressed in only 2.1% of the cases. Examples 
of immunoreactivity of CD44+, CD24+, Ki-67 and claudin-7 
are displayed in Fig. 1.
To determine if the expression of CD44 and CD24 is 
associated with tumor characteristics the clinicopathological 
Figure 1. Immunopositivity of ductal invasive breast carcinomas for CD44, CD24, Ki-67 and claudin-7 (x200).
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features and biological markers were compared in the CD44 
and CD24 positive and negative cases (Table III).
Presence of CD44 was not associated with ER, PR, Ki-67, 
claudin-7 nor with clinical characteristics, but a marginal 
association with high grade (P=0.08) was observed (Table III). 
Positive expression of CD24 was associated with ER (P=0.05), 
PR (P=0.02) and Ki-67 positivity (P=0.01). There was a trend 
although not statistically significant, for the presence of CD24 
to correlate with claudin-7 and CK18.
Cases were categorized into four phenotypes according 
to CD44 and CD24 positive/negative expression. Of the 95 
patients, 8 (8.4%) were categorized into the CD44+/CD24- 
phenotype; the proportion of double positive (CD44+/CD24+) 
and double negative (CD44-/CD24-)tumors was 43 (45.3%) 
and 6 (6.3%) respectively, while the CD44-/CD24+ phenotype 
was detected in 16.8% of the tumors (Table II).
We used an immunohistochemical surrogate for the gene 
array expression to define the subgroups of breast carcinoma. 
Among 95 IDC, a total of 47 tumors were categorized within 
the luminal subgroups: luminal A (25.3%) and luminal B 
(24.2%); 20 (21.5%) of 95 had a triple negative profile and the 
HER2 subgroup contributed to 9.5% of the tumors (Table II).
Next, we explored the expression of CD44/CD24 phenotypes 
across the breast cancer subgroups (Table IV). No associa-
tion with a particular subtype of breast cancer was observed. 
However, CD44+/CD24- expression was more common in 
the triple negative subgroup, absent in the HER2+ group and 
presented a low frequency in the luminal B subgroup (10%). 
Double positive tumors were more frequent in the luminal 
subgroups, and we noted that these subgroups contained a high 
proportion of CD44-/CD24+ cells. Our evaluation did not show 
any association of the frequency of different phenotypes with 
the clinicopathological parameters, pTNM stage, lymph node 
status, CK7, CK5, CK18, claudin-7 expression. However, we 
observed a marginal association (P=0.08) of a high propor-
tion of double positive cases with high nuclear grade and of 
Ki-67 positive frequency with CD44-/CD24+ tumors (P=0.06). 
Concerning the association with the frequency of metastasis, 
the higher frequency was related to the CD44+/CD24+ pheno-
type (82.4%) followed in descending order by CD44-/CD24+ 
(11.8%), CD44-/CD24- (5.9%) and CD+/CD24- (0%).
We also evaluated whether the expression of claudin-7, 
Ki-67, CK5 and CK18 differed in the tumor subgroups 
(Table V). Results indicated a similar frequency of Ki-67 
Table II. Frequency of immunostaining among arrayed breast 
carcinoma cases.
Parameters Patients (%)
Estrogen receptor
 Positive 45 (47.4)
 Negative 35 (36.8)
 ND 15 (15.8)
Progesterone receptor
 Positive 45 (47.4)
 Negative 35 (36.8)
 ND 15 (15.8)
HER2
 Positive 33 (34.7)
 Negative 51 (53.7)
 ND 11 (11.6)
Ki-67
 Positive 45 (47.4)
 Negative 40 (42.1)
 ND 10 (10.5)
CD44
 Positive 55 (57.9)
 Negative 23 (24.2)
 ND 17 (17.9)
Phenotypes
 CD44+/CD24+ 43 (45.3)
 CD44+/CD24- 8 (8.4)
 CD44-/CD24+ 16 (16.8)
 CD44-/CD24- 6 (6.3)
 ND 22 (23.2)
CD24
 Positive 71 (74.7)
 Negative 19 (20.0)
 ND 5 (5.3)
Claudin-7
 Positive 37 (38.9)
 Negative 49 (51.6)
 ND 9 (9.5)
CK5
 Positive 17 (17.9)
 Negative 68 (71.6)
 ND 10 (10.5)
CK6
 Positive 2 (2.1)
 Negative 80 (84.2)
 ND 13 (13.7)
CK18
 Positive 58 (61.1)
 Negative 27 (28.4)
 ND 10 (10.5)
Table II. Continued.
Parameters Patients (%)
Subgroups
 Luminal A 24 (25.3)
 Luminal B 23 (24.2) 
 HER2 9 (9.5)
 Triple negative 20 (21.5)
 ND 19 (20.0)
HER2, human epidermal growth factor receptor 2; CK, cytokeratin; 
ND, not known.
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(P=0.47) in all 4 subgroups; cytokeratin 18 (CK18) expression 
was clearly associated to the luminal cases (P=0.003) and 
CK5 positivity was more common in HER2 and triple negative 
tumors (P=0.1). However, only 30% (n=4) of the triple nega-
tive tumors displayed CK5 immunoreactivity, emphasizing the 
small number of basal tumors in our tumor material. Positive 
claudin-7 was less frequent in the triple negative subgroup.
Claudin-7 was not associated with known prognostic 
parameters such as pTNM, nuclear grade or nodal status, 
but on the other hand, showed a trend toward the presence of 
metastasis (P=0.07). Claudin-7 was very likely to be positive 
in HER2 positive tumors (P=0.07), and was inversely asso-
ciated to progesterone receptor (P=0.02) and CK5 presence 
(P=0.03) (Table VI).
Table III. Association of CD44 and CD24 expression in breast carcinomas with clinicopathological characteristics and biological 
markers.
 CD44 CD24
 ------------------------------------------------------------ ------------------------------------------------------------
Parameters Negative (%) Positive (%) P-valuea Negative (%) Positive (%) P-valuea
pTNM
 I/II 14 (35.0) 26 (65.0) 0.31 13 (28.3) 33 (71.7) 0.12
 III 8 (22.2) 28 (77.8)  6 (14.0) 37 (86.0)
Nuclear grading
 I 0 (0) 2 (100.0)  1 (50.0) 1 (50.0)
 II 14 (41.2) 20 (58.8) 0.08 8 (21.6) 29 (78.4) 0.52
 III 8 (19.5) 33 (80.5)  9 (18.0) 41 (82.0)
Nodal status
 Positive 16 (34.0) 31 (66.0) 0.30 13 (22.8) 44 (77.2) 0.79
 Negative 6 (20.7) 23 (79.3)  6 (18.8) 26 (81.3)
Estrogen receptor
 Positive 11 (26.2) 31 (73.8) 0.79 5 (11.4) 39 (88.6) 0.05
 Negative 9 (31.0) 20 (69.0)  10 (30.3) 23 (69.7)
Progesterone receptor
 Positive 7 (21.9) 25 (78.1)  0.42 2 (6.1) 31 (93.9) 0.02
 Negative 12 (32.4) 25 (67.6)  12 (27.3) 32 (72.7)
HER2
 Positive 6 (19.4) 25 (80.6) 0.12 5 (16.7) 25 (83.3) 1.00
 Negative 16 (39.0) 25 (61.0)  10 (19.6) 41 (80.4)
Ki-67
 Positive 13 (31.0) 29 (69.0) 1.00 4 (9.3) 39 (90.7) 0.01
 Negative 9 (28.1) 23 (71.9)  13 (33.3) 26 (66.7)
Claudin-7
 Positive 6 (18.8) 26 (81.3) 0.12 4 (11.8) 30 (88.2) 0.17
 Negative 15 (35.7) 27 (64.3  13 (26.5) 36 (73.5)
CK5
 Positive 4 (28.6) 10 (71.4) 1.00 2 (12.5) 14 (87.5) 0.51
 Negative 17 (28.8) 42 (71.2)  14 (21.5) 51 (78.5)
CK6
 Positive 0 (0) 2 (100.0) 1.00 0 (0) 1 (100.0) 1.00
 Negative 19 (27.9) 49 (72.1)  14 (18.2) 63 (81.8)
CK18
 Positive 12 (24.5) 37 (75.5) 0.28 9 (15.8) 48 (84.2) 0.14
 Negative 9 (37.5) 15 (62.5)  8 (32.0) 17 (68.0)
HER2, human epidermal growth factor receptor 2; CK, cytokeratin; astatistical significance was determined by the χ2 test. P-values (two-sided) 
<0.05 were considered statistically significant and are indicated in bold.
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To determine whether CD24 and CD44 and their combined 
phenotypes may affect overall survival (OS) and disease-free 
survival (DFS), we constructed Kaplan-Meier survival curves 
which were analyzed statistically (log-rank test). The median 
follow-up for this study was 4.8 years (range, 0.36-10.9 years).
When the analysis was performed according to the 
frequency of combined phenotypes we found that they did not 
have an impact on patient DFS or OS. However, we observed 
that the CD44+/CD24- phenotype was more favorable with 
respect to OS (87.5% of patients alive) or DFS (100% without 
metastasis) while the CD44-/CD24+ phenotype indicated a 
poorer survival (53.3% of alive patients) and reduced DFS 
(83% without metastasis).
No influence of CD44+ immunophenotype on OS or DFS 
was observed. Considering the single CD24+ phenotype we 
noted no association with OS, but there was a significant 
association to a reduction of DFS, although a border line one 
(P=0.07). CK5, CK18 and Ki-67 expression had no influence 
in OS or DFS. However, claudin-7 positivity although not 
statistically associated with OS, was associated with reduced 
DFS. 62.9% for positive claudin-7 vs. 82.5% for claudin-7 
negative (P=0.05). Claudin-7 positivity was also related to a 
Table IV. Distribution of phenotypes according to immunohistochemically-defined subgroups of invasive ductal carcinomas, 
clinicopathological features and biological markers.
  CD44+/CD24+ CD44+/CD24- CD44-/CD24+ CD44-/CD24-
Parameters n (%) n (%) n (%) n (%) P-valuea
Luminal A
 HER2-/ER+ or PR+ 12 (57.1) 1 (4.8) 7 (33.3) 1 (4.8)
Luminal B
 HER2+/ER+ or PR+ 14 (70.0) 2 (10.0) 3 (15.0) 1 (5.0) 0.30
HER2+/ER- and PR- 6 (85.7) 0 (0) 0 (0) 1 (14.3)
Triple negative  7 (38.9) 4 (22.2) 5 (27.8) 2 (11.1)
pTNM
 I + II 21 (55.3) 4 (10.5) 7 (18.4) 6 (15.8) 0.12
 III 22 (64.7) 4 (11.8) 8 (23.5) 0 (0)
Nuclear grading
 I 1 (50.0) 1 (50.0) 0 (0) 0 (0) 0.08
 II 16 (51.6) 2 (6.5) 8 (25.8) 5 (16.1)
 III 26 (66.7) 5 (12.8) 8 (20.5) 0 (0)
Nodal status
 Positive 25 (56.8) 4 (9.1) 10 (22.7) 5 (11.4) 0.57
 Negative 18 (64.3) 4 (14.3) 5 (17.9) 1 (3.6)
Metastasis
 M0 24 (53.3) 7 (15.6) 10 (22.2) 4 (8.9) 0.16
 M1 14 (82.4) 0 (0) 2 (11.8) 1 (5.9)
Ki-67
 Positive 24 (60.0) 3 (7.52) 12 (30.0) 1 (42.1) 0.06
 Negative 17 (54.8) 5 (16.1) 4 (12.9) 5 (16.1)
Claudin-7
 Positive 20 (69.0) 3 (10.3) 5 (17.2) 1 (3.4) 0.5
 Negative 22 (52.4) 5 (11.9) 11 (26.2) 4 (9.5)
CK5
 Positive 8 (61.5) 1 (7.7) 3 (23.1) 1 (7.7) 0.98
 Negative 34 (60.7) 6 (10.7) 11 (19.6) 5 (8.9)
CK18
 Positive 32 (66.7) 4 (8.3) 9 (18.8) 3 (6.3) 0.22
 Negative 9 (40.9) 4 (18.2) 6 (27.3) 3 (13.6)
HER2, human epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone receptor; CK, cytokeratin; astatistical significance 
was determined by the χ2 test. P-value (two-sided) <0.05 was considered statistically significant.
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higher frequency of metastatic tumors (65%) as compared to 
claudin-7 negativity (40%, P=0.07). When we analyzed the 
distribution of cases relative to their subgroup profiles, we 
observed a larger proportion of patients who died or relapsed 
in the HER2 subgroup (P=0.03) within the follow-up period, 
whereas no differences in OS or DFS was verified among the 
other subgroups (Figs. 2 and 3).
Discussion
In this study we used a tissue microarray to examine the 
expression of hormone receptors and HER2 in 95 cases of 
invasive ductal carcinoma and categorized these cases into 
subgroups based on immunohistochemistry analysis. Next, we 
determined the expression of CD44 and CD24 in our tumor 
series and analyzed the association of these phenotypes with 
the different subgroups. 
We found that luminal groups were the most common 
immunohistochemical subtypes within the range of other 
studies. There was also no significant association between 
subtypes and clinicopathological features, consistent with 
previous reports (18). In accordance to recent findings (19,20), 
the HER2-overexpressing subtype showed the worst OS and 
DFS, but the survival rate of patients with triple negative 
carcinomas was not different from that of other groups except 
for the HER2-overexpressing subtype. The luminal A group 
of patients showed an unexpectedly low OS and DFS. As in 
our study, this subgroup showed a high metastasis frequency 
(33.3%) as compared to the other subgroups and displayed a 
high proliferation score. These features may have contributed 
to the observed worse prognosis.
In contrast to results of Al-Hajj et al (9) reporting CD44+/
CD24- cells in all breast carcinomas studied, our evaluation 
of the conventional stem cell phenotype (CD44+/CD24-) indi-
cated that only 8.4% of the analyzed tumors expressed this 
phenotype. The frequency of stem cells was expected to be 
low (21) and our frequency rate is lower than those reported by 
several authors (11,15,16,22). Analysis of several human breast 
cancer cell lines indicated that this particular phenotype was 
exhibited by only 25% (2/8) of the cell lines (23).
Table V. Distribution of biological markers in accordance with the molecular subgroups defined by immunohistochemical fea-
tures of breast carcinoma.
 Luminal A Luminal B
  (HER2-/ER+ or PR+) (HER2+/ER+ or PR+) HER2+/ER- and PR- Triple negative
Parameters n (%) n (%) n (%) n (%) P-valuea
Claudin-7
 Positive 11 (45.8) 14 (60.9) 5 (55.6) 6 (30.0) 0.22
 Negative 13 (54.2) 9 (44.4) 4 (44.4) 14 (70.0)
Ki-67
 Positive 14 (60.9) 15 (65.2) 5 (55.6) 8 (42.1) 0.47
 Negative 9 (39.1) 8 (34.8) 4 (44.4) 11 (57.9)
CK5
 Positive 4 (17.4) 2 (8.7) 4 (44.4) 6 (31.6) 0.10
 Negative 19 (82.6) 21 (91.3) 5 (55.6) 13 (68.4)
CK18
 Positive 18 (78.3) 20 (87.0) 5 (55.6) 7 (36.8) 0.003
 Negative 5 (21.7) 3 (13.0) 4 (44.4) 12 (63.2)
Nodal status
 Positive 17 (73.9) 12 (54.5) 6 (66.7) 12 (60.0) 0.58
 Negative 6 (26.1) 10 (45.5) 3 (33.3) 8 (40.0)
pTNM
 I 2 (8.3) 3 (13.0) 1 (11.1) 1 (5.0) 0.96
 II 9 (37.5) 10 (43.5) 4 (44.4) 9 (45.0)
 III 13 (54.2) 9 (39.1) 4 (44.4) 9 (45.0)
 IV 0 1 (4.3) 0 (0.0) 1 (5.0)
Metastasis
 M0 14 (63.6) 16 (84.2) 1 (14.3) 15 (75) 0.05
 M1 8 (33.3) 3 (13.0) 13 (13.0) 2 (10.0)
HER2, human epidermal growth factor receptor 2; astatistical significance was determined by the χ2 test. A P-value (two-sided) <0.05 was 
considered statistically significant and is indicated in bold.
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Several studies have delineated that the CD44+/CD24- status 
is associated with the basal-like or triple negative subgroups of 
breast cancer (11,12,14,24). Although in our study this phenotype 
was more common in the triple negative subgroups, no statistical 
significance was seen in the comparison between phenotypes 
and subgroups. We also did not find an association with known 
prognostic parameters (pathological stage, nuclear grade and 
nodal status). Our results confirmed previous reports (11,15,16).
Figure 2. Overall survival and disease-free survival in all patients according to: CD44 (A and D); CD24 (B and E); and CD44/CD24 (C and F).
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Moreover, the HER2 subgroup which in our results 
presented the worst prognosis in terms of overall survival and 
disease-free recurrence was negative for the CD44+/CD24- 
phenotype. Similar results have been previously reported 
suggesting that other markers indicative of a cancer stem cell 
for HER2 remain to be identified (11).
Other studies have indicated that CD44+/CD24- breast 
cancer cell lines have highly invasive and metastatic proper-
ties (14,25,26) and thus should correlate with poor prognosis. 
We did not observe any association of CD44+/CD24- in tumors 
expressing clinicopathological parameters of prognosis or 
with the potential to progress or recur or with high frequency 
of metastasis according to other reports (10,15,16,22,27).
In view of these results, we suggest that features of CD44+/
CD24- tumors in our study are not concordant with tumori-
genic properties reported to characterize cancer stem cells 
(9) and therefore, are consistent with the ones suggesting that 
CD44+/CD24- may not have the ability to identify cancer stem 
cells. These results highlight the need of other markers for the 
evaluation of cancer stem cells. Similar suggestions have been 
made by Mylona et al (15), Abraham et al (16) and Hwang-
Verslues et al (23).
On the other hand, although the CD44-/CD24+ phenotype 
has failed to identify a statistically significant association with 
overall survival, we noted a tendency of patients harboring 
CD44-/CD24+ tumors to present a worse prognosis. Moreover, 
despite the lack of relation to survival we found that CD24+ 
alone was a prognostic indicator of decreased disease-free 
survival time, confirming results of a recent report (22).
The CD24 protein was expressed in several solid tumors. 
This protein has been associated with bad disease prognosis 
and metastatic behavior for several solid tumors including 
breast cancer (27-30). CD24+ has also been associated with 
proliferation, adhesion and invasion in MCF-7 cells (31). We 
verified a statistical association between CD24+ and Ki-67 
(P=0.01). Therefore, its seems that CD24+ is associated with 
an aggressive tumor behavior in spite of retaining a differenti-
ated luminal epithelial cell phenotype and our data indicate 
a significant association between CD24+ with ER+, PR+ and a 
marginal one with CK18.
Among the proteins analyzed in order to determine the 
association of its expression with the different phenotypes 
of breast cancer, claudin-7 expression was noteworthy, as a 
decreased expression of claudin-7 correlated with higher tumor 
Figure 3. Overall survival and disease-free survival in all patients based on immunohistochemical subgroups (A and B) and claudin-7 (C and D).
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grade and metastatic disease (32). Moreover, the claudinlow 
subtype, which has recently emerged in the molecular classifi-
cation of breast cancer, is characterized by reduced expression 
of claudins including claudin-7 (6).
However, we did not find an association between claudin-7 
with different phenotypes, or with overall survival. On the other 
hand, claudin positive carcinomas relapsed more frequently 
than claudin negative ones, (P=0.05). Although this observa-
tion seems to contradict the hypothesis that claudinlow cells are 
associated to poor outcome tumors, it is consistent with two 
recent studies that have highlighted the association of preserved 
claudin-4 and claudin-1 with poor prognosis in breast cancer 
(33,34).
In conclusion, our results suggest that the frequency of 
CD44+/CD24- tumor cells in breast cancer may not be asso-
ciated to outcome. Both CD24 and claudin-7 positivity were 
associated to reduced time of recurrence suggesting that these 
two investigated markers can be used in combinations with 
other clinicopathological information to improve the assess-
ment of prognosis in breast carcinoma.
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